Skip to main content
Tag

FDA

2010 Potpourri XXXIV

By Commentary No Comments

On the menu for this week’s potpourri–savings from wellness efforts for a large employer; drug reimbursement for Medicaid programs; using remote monitoring in a health plan context; the FDA’s regulatory approach to mobile health uses; the effect of tort reform on imaging rates and hepatitis C pay-for-performance measures.

Read More

FDA’s Review of the 510(k) Process

By Commentary No Comments

The Food and Drug Administration has been reviewing its 510(k) process, which is used for many medical device approvals. Two preliminary reports contain a series of recommendations designed to provide greater predictability in the process, while ensuring identification of significant safety concerns.

Read More

GAO Report on Genetic Testing

By Commentary No Comments

Personalized medicine relies on genetic testing for much of its information. Direct-to-consumer genetic testing firms are widespread and a GAO report reveals that much of their work appears shoddy and their marketing deceptive. More regulation appears needed and on the way.

Read More